Seres Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Seres Therapeutics

03/05/2024 14:46

* Seres Therapeutics Inc  MCRB.OQ   MCRB.O  is expected
to report
resultson May 7 (estimated) for the period ending March 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
revenue of $250 thousand, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Seres Therapeutics Inc
is for
a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Seres
Therapeutics Inc is $7.00​, above​ its last closing price
of $1.11. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.40       -0.50      -0.32     Beat    35.6
 Sep. 30 2023  -0.49       -0.50      -0.37     Beat    26.2
 Jun. 30 2023  0.53        0.53       0.36      Missed  -32.6​
 Mar. 31 2023  -0.56       -0.55      -0.57     Missed  -3.8
 ​​Dec.        -0.30       -0.46      -0.54     Missed  -16.1
 31 2022                                                
 Sep. 30 2022  -0.50       -0.47      -0.49     Missed  -4.5​
 Jun. 30 2022  -0.59       -0.60      -0.70     Missed  -17.4
 Mar. 31 2022  -0.54       -0.52      -0.61     Missed  -16.4
 This summary was machine generated May 3 at 13:46 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)